Corporate profile

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. We classify our products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships

Our Radiopharmaceutical Oncology products help healthcare professionals Find, Fight and Follow cancer. 

Our leading Precision Diagnostic products assist healthcare professionals to Find and Follow diseases, with a focus in cardiology. 

Our Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms.

Our commercial products are used by nuclear medicine physicians, oncologists, radiologists, urologists, cardiologists, internal medicine physicians, sonographers and technologists working in a variety of clinical settings. 

Lantheus is headquartered in Massachusetts, with additional offices in New Jersey, Canada, Germany, Sweden, Switzerland and the United Kingdom.

$

Minimum 15 minutes delayed. Source: LSEG

Latest press releases

February 12, 2026

Lantheus to Host Fourth Quarter and Full Year 2025 Earnings Conference Call and Webcast on February 26, 2026, at 8:00 a.m. Eastern Time

January 2, 2026

Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies

November 24, 2025

Lantheus to Present Florbetaben F 18 Data at CTAD 2025

Events

Feb 26, 2026 8:00 AM EST

Q4 2025 Lantheus Earnings Conference Call

See all

Supplemental financial information

Nov 06, 2025

Selected Historical Financial Results

Nov 06, 2025

3Q 2025 Reconciliation of GAAP to Non-GAAP Financial Measures

Aug 06, 2025

2Q 2025 Reconciliation of GAAP to Non-GAAP Financial Measures

See all